The first time geneticist George Church visited Siberia was the first summer the permafrost melted.
Permafrost by its nature is supposed to stay frozen year-round, but in a marker of encroaching climate change, in 2018 the top layer of soil thawed and didnt refreeze. Microbes began to eat the carbon that had been locked away in the ice and released it into the air as methane gas. Church watched a teammate light a match and ignite a pocket of the gas that hovered over the softening bog they stood in.
That was an ominous sign, Church recalled. Today, he says, thawing permafrost is burping up methane at an alarming rate, given that the gas is 30 times more potent than carbon dioxide in contributing to global warming.
The sight reinforced Churchs determination to combat climate change by ensuring that the worlds permafrost stays frozen, keeping its estimated 1.4 trillion tons of stored carbontwo and a half times more than the Amazon rainforest harborstucked safely away.
His plan for doing so: Genetically modifying a group of elephants to thrive in the cold and moving them north so their daily activities contribute to preserving and restoring Arctic environments.
Harvard Medicine News spoke with Church about this unusual approach to climate mitigation and the latest developments in his labs efforts. Church is the Robert Winthrop Professor of Genetics in the Blavatnik Institute at Harvard Medical School and a founding core member of the Wyss Institute for Biologically Inspired Engineering at Harvard University.
Church: People tend to use the shorthand that were de-extincting mammoths: bringing them back to life after the last of them died about 4,000 years ago. Were not. At least, not in the near future. Were trying to de-extinct genes. The field has actually already done this with two genes that confer cold-resistant properties to organisms. The idea is to safely introduce these and other genes into present-day elephants so the elephants can comfortably live in and restore Arctic environments.
Church: The main reasons have to do with biodiversity and climate mitigation.
A question we get asked frequently is, Why de-extinct something that already had its chance; why dont you focus on endangered species and saving them from going extinct? Well, thats exactly what were doing. Were dealing not with mammoths but with modern endangered species.
All elephant species are endangered. Were trying to give them new land in the Arctic thats far away from humans, who are the major culprits causing extinction. Were trying to cure Asian elephant-specific herpesvirus, which can be deadly, especially in young elephants. Were trying to develop tools that might be useful for other endangered species that other teams might be interested in working on.
The two-for-one is that not only would the elephants get a new homeland, but their homeland is in desperate need of environmental restoration, and they can help. Moving genetically adapted elephants to the Arctic offers an opportunity to sequester, or remove from the atmosphere, significant amounts of carbon and to prevent more carbon from escaping.
Understanding how this might work requires connecting a few dots. Elephants knock over trees, reducing bark that absorbs sunlight and heats the ground. Clearing a portion of the tree cover allows the animals to walk through new areas and pack down the snow there, facilitating permafrost freeze. Otherwise, the snow forms a fluffy, insulating layer that keeps the topsoil warm.
Basically, the idea is that we need to convert a portion of trees in the Arctic back to grass, and elephants are the only living large herbivore that will do that. They do so quickly and easily, and they like doing it. So a genetically adapted elephant-mammoth hybrid might prove to be a good proxy species for the ecological role the woolly mammoth used to play.
Church: Were trying to gather genetic diversity. We know diversity is useful for survival in a changing or new environment, and were getting better at identifying and gathering genes that are important for a given traitin this case, cold tolerance and virus resistance.
Were no longer limited to searching for beneficial genes in one elephant herd or even the global elephant population; now we can go all around the world, even to distant species, and back in time up to 1 million years to discover and obtain those genes. The DNA that mammoths left behind in their bones can offer us the genetic code for traits like warm, woolly hair and thick, subcutaneous fat.
Church: Most of the projects Ive worked on in my careerlike the publicizing and privacy of personal genomes, development of devices that print synthetic DNA, gene drives that eliminate malaria parasites from mosquitoesrequire broad public engagement. The problem isnt always getting scientists engaged; its getting the public engaged. People are focused on how to put food on the table and get their kids educated. The latest cutting-edge scientific thing is not always perceived as important.
As a start, my research group has worked with HMS geneticist Ting Wus Personal Genetics Education Project to brief Congressional staffers, who then bring information back to their constituents. Were working with writers who reach millions of people through their narrativesand the Arctic elephant story resonates particularly well. Were reaching out to representatives of key populations, including people from Indigenous groups, Arctic farming communities, other industries, and governments. Well engage with anyone who wants to participate, whether they take a positive or negative view of the work.
Church: I am a scientific co-founder of Colossal but have no management role there. The company is providing funding for my labs work toward creating an elephant-mammoth hybrid through a sponsored research agreement with Harvard. Its fairly open-ended research that we would have done anyway if wed had the money for itin fact, we were already doing some of the work through sparsely funded or volunteer labor. Now that Colossal has dedicated some funding to it, this work in my lab is a much more concerted and defined project that well be pursuing over the next few years.
Church: Definitely. First of all, climate change itself is a human health issue. Preventing further warming or reversing existing damage by sequestering carbon would safeguard human lives along with the ecosystems.
Side products of the Colossal effort will be technologies from my lab, with an additional potential for great impact on human health. Some of what were doing with reproductive medicine in elephants, like making gametes and finding ways to handle premature births, may open a path into various assistive reproductive technologies in humans, making those procedures safer for all sorts of cases.
There is a lot that human medicine and animal medicine can learn from one another. Weve seen in the past that a lot of our work on reading and writing DNA and developing medical diagnostics and therapeutics is directly translatable to veterinary efforts.
Church: Our lab does a lot of basic engineering and a little bit of basic science, and were heavily dependent on basic science from our close colleagues. An example of such pure science was the discovery of a repetitive family of gene sequences now called CRISPR. That was seen as just a bunch of junk DNA at first, and now it has revolutionized our ability to edit genes for medical and industrial purposes. The genomic sequencing of lots of vertebrate species, including extinct species, was basic science without necessarily any particular goal in mind, and that has been very valuable.
Church: Were trying to efficiently identify and test genes that would provide adaptation to Arctic environments. Weve been developing methods for multiplexed editingthe ability to make thousands of genetic and epigenetic changes at once. This allows us to turn adult elephant cells into pluripotent stem cells, introduce the changes, and mature the cells back into adult-like tissues fast, within four days to a couple of weeks, so we can then study our genes of interest as a batch. Speed and volume are important because introducing a single change and waiting for an entire elephant embryo to mature would take 22 months. In the time it would take to study every gene candidate that way, the climate crisis would either be resolved by some other method or have caused societal collapse.
Our record for multiplexed editing in general now is 22,000 edits in a few days. The number of edits well need to make in the elephant isnt clear yet. It could be as few as 40, which is the number of changes we made in the pig genome to facilitate organ transplantation to humans, and it probably wont be more than 500,000, which is the number of fixed genetic differences between mammoths and elephants.
Were also pushing the science forward on reprogramming techniques to grow healthy gametes and promote safe in vitro fertilization and embryonic development so that when the research is ready to deploy, elephants can successfully gestate the genetically modified offspring. Because we dont want to hinder the reproduction of endangered species.
Church: The big ones are the multiplexed editing and both accelerated and normal in vitro development. For initial testing, you want accelerated development. For complete testing and to ultimately birth calves, you need normal-speed development.
Getting ready for further down the road: Strategies are being developed for where the elephants should be located, how to guide them away from places where people live and toward places where they could contribute to reducing carbon risk, and what the appropriate landscapes and flora should be, including specific flowering plants they like to eat. These behavioral and geopolitical realities might take more time than the actual engineering.
People with sophisticated modeling tools want to be involved. Its better to find out now with a good model whether theres a problem than six years from now. Carbon reserves vary from place to place in the Arctic, and it might take dispersing elephants over only a small fraction of its 20 million square kilometers, in precisely targeted areas, to get the climate impact we want.
Church: The six-year estimate for birthing an Arctic-adapted elephant calf is an ideal-case scenario based on working backwards from the 22-month gestation period, figuring another two years to achieve successful IVF embryos in mice, and two years in between for debugging the system for producing healthy elephant fetal development. That assumes everything goes smoothly along the way, which doesnt typically happen.
I used to predict that reaching the final stage would take a very long time, maybe decades, because we didnt have any appreciable funding, and it does depend on funding. Today, I think six years is a good goal to strive forbut its not a promise. Its a similar kind of ambitious, engineering-focused, team-based target that President Kennedy set when he declared we would put a person on the moon within a decade. The scientific challenges of this project are considerable but ultimately surmountable. The bioethical dimensions are paramount. The execution will no doubt be daunting. However, we owe it to science, to humankind, to our fellow species, and to our planet to try.
This interview was edited for length and clarity.
Here is the original post:
A mammoth solution - Harvard Office of Technology Development
- Overview: Gene Structure - Holland-Frei Cancer Medicine ... - December 23rd, 2021
- Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better? - Forbes - December 23rd, 2021
- Triangle gene editing firms CEO: There is a revolution occurring in medicine - WRAL TechWire - December 23rd, 2021
- Integra Therapeutics Q&A: building next-generation gene editing tools - pharmaceutical-technology.com - December 23rd, 2021
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 23rd, 2021
- Gene Mutation Found that is Linked to the Development of Kidney Disease - Clinical OMICs News - December 23rd, 2021
- Vaccines are just the beginning for RNA. The technology is being tested on heart and liver diseases. - The Philadelphia Inquirer - December 23rd, 2021
- A look at prospects for the US gene therapy industry - BioPharma-Reporter.com - December 23rd, 2021
- Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of... - December 23rd, 2021
- Betagenon co-founder publishes that AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced... - December 23rd, 2021
- CUIMC Year in Review: Health News - Columbia University Irving Medical Center - December 23rd, 2021
- EP. 6B: Phenotypic Theranostics in the Future of Precision Medicine - Targeted Oncology - December 23rd, 2021
- Emendo Biotherapeutics and Seattle Children's Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe... - December 23rd, 2021
- Open letter to employees, technologists, professionals and physicians of the Optilab laboratory medicine clusters in Quebec - McGill University Health... - December 23rd, 2021
- First variant of concern evolved to evade immune system - EurekAlert - December 23rd, 2021
- Double vaccinated and still infected with Omicron? Heres how long you should isolate - The Indian Express - December 23rd, 2021
- Genetic Tests Prompt Therapy Adjustments in Epilepsy - Medscape - December 22nd, 2021
- How to Know What Strain of COVID-19 You Have - Do Doctors Know What Variant You Have? - Prevention.com - December 22nd, 2021
- Low expression of PLAT in Breast cancer | IJGM - Dove Medical Press - December 22nd, 2021
- Outlook on the Advanced Therapy Medicinal Products CDMO Global Market to 2028 - Rising Number of Clinical Trials for ATMP is Driving Growth -... - December 22nd, 2021
- MiNA Therapeutics Appoints Two Independent Directors With Extensive Industry Experience to Support Next Phase of Growth - BioSpace - December 22nd, 2021
- New gene therapy could provide cure for sickle cell disease, according to UAB study - The Mix - December 19th, 2021
- Durham gene therapy plant to help Pfizer develop treatments for rare diseases - WRAL Tech Wire - December 19th, 2021
- Researchers zero in on therapeutic target for aggressive uterine cancer - Michigan Medicine - December 19th, 2021
- Generation Bio shares halved as hemophilia gene therapy hunt goes back to square one - FierceBiotech - December 19th, 2021
- URMC & RIT faculty awarded patent for gene transfer technology that could transform cancer therapies - URMC - December 19th, 2021
- Very important pharmacogene variants in the Blang population | PGPM - Dove Medical Press - December 19th, 2021
- Gene Sequencing Market Research, Analysis and Global Study |Roche, Johnson & Johnson, Illumina, Thermo Fisher Scientific - Digital Journal - December 19th, 2021
- Global Gene Editing Market Research Report 2021 Featuring CRISPR, GenScript, Horizon Discovery Group, Integrated DNA Technologies and New England... - December 19th, 2021
- Association between the anti-aging protein klotho with sleep | IJGM - Dove Medical Press - December 19th, 2021
- Covid-19: 7 Nigeria returnees admitted to Chennais Kings Institute of Preventive Medicine for suspected - Free Press Journal - December 19th, 2021
- Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing Technology as New Category in Genetic... - December 13th, 2021
- Rare gene mutation in some Black Americans may allow earlier screening of heart failure - National Institutes of Health - December 13th, 2021
- Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia... - December 13th, 2021
- On the hunt for new ALS drugs, researchers see progress, and a long road ahead - BioPharma Dive - December 13th, 2021
- Europe Cell and Gene Therapy Market Size to Reach Revenues of USD 2.9 Billion by 2026 - Arizton - PRNewswire - December 13th, 2021
- Researchers Dig Up Genes and Cells Related to Skull Formation in Mice - Genetic Engineering & Biotechnology News - December 13th, 2021
- Syrian refugee is thriving five years after last-gasp gene therapy - STAT - STAT - December 13th, 2021
- The perils of flawed research and the ivermectin debacle - Medical News Today - December 13th, 2021
- Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision... - December 13th, 2021
- Why Does The COVID-19 Virus 'Escape' From Our Immune Systems? - Texas A&M University Today - December 13th, 2021
- Hydra DNA Reveals Theres More Than One Way to Regrow a Head - The New York Times - December 13th, 2021
- Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH... - December 13th, 2021
- Use of Race in Clinical Diagnosis and Decision Making: Overview and Implications - Kaiser Family Foundation - December 13th, 2021
- Identification of Significantly Expressed Gene Mutations for Automated Classification of Benign and Malignant Prostate Cancer - DocWire News - December 13th, 2021
- VUMC: Gene Discoveries Give New Hope To People Who Stutter - Cannon Courier - December 13th, 2021
- Relationship among Homocysteine, Inflammation in AIS | NDT - Dove Medical Press - December 13th, 2021
- Groundbreaking Experimental Compound Displays Effectiveness in Treating Symptoms of Autism and Alzheimers Disease - SciTechDaily - December 13th, 2021
- '90 Day Fianc: Before the 90 Days': Everything to Know About Alina's Rare Medical Condition Diastrophic Dysplasia - Showbiz Cheat Sheet - December 13th, 2021
- Cincinnati Children's teams up with CTI on cell and gene therapies - The Lane Report - December 7th, 2021
- Is 'personalised medicine' the future of healthcare? - Tatler - December 7th, 2021
- Francis Collins on medical advances, vaccine hesitancy and Americans' ill health : Shots - Health News - NPR - December 7th, 2021
- Gene Expression Analysis Market: Rise in the need for personalized medicine is likely to influence the global market - BioSpace - December 7th, 2021
- Atamyo Therapeutics Obtains First Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-100, its Gene Therapy to Treat Limb-Girdle... - December 7th, 2021
- Gyroscope Therapeutics Announces Appointment of Tony Adamis to Board of Directors - Business Wire - December 7th, 2021
- Tune Therapeutics Launches with Pioneering Epigenomic Control Platform to Master Gene Networks, Treat Broad Range of Diseases - PRNewswire - December 7th, 2021
- Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide)... - December 7th, 2021
- The top 10 health and medicine breakthroughs of 2021 - Popular Science - December 7th, 2021
- SNPs rs251124, rs2287926, and rs173686 with IA | NDT - Dove Medical Press - December 7th, 2021
- Potential New Therapeutic Option May Combat Drug Resistance in HER2+ Breast Cancer and Ovarian Cancer - Cancer Network - December 7th, 2021
- Penn's Medical Emergency Response Team, 'prepared for anything' | Penn Today - Penn Today - December 7th, 2021
- Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in Kids - HealthDay - November 21st, 2021
- Immunosuppressants linked to severe reactions in people with common genetic profile - Stanford Medical Center Report - November 21st, 2021
- A video that originated on InfoWars is filled with falsehoods about COVID-19 vaccines - PolitiFact - November 21st, 2021
- Gene signature may give an upper hand in metastatic breast cancer - Baylor College of Medicine News - November 21st, 2021
- Lung cancer management in the era of precision medicine - Express Healthcare - November 21st, 2021
- Powerful gene-based testing by integrating long-range chromatin interactions and knockoff genotypes - pnas.org - November 21st, 2021
- Stoke Therapeutics Announces Presentations from the Company's Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting - Business... - November 21st, 2021
- European Commission approves Roche's Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer |... - November 21st, 2021
- Maternal cannabis use is associated with suppression of immune gene networks in placenta and increased anxiety phenotypes in offspring - pnas.org - November 21st, 2021
- Vertex Announces Reimbursement Agreement in Spain for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With... - November 21st, 2021
- Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled... - November 21st, 2021
- Gene Therapy and Genetic Engineering - MU School of Medicine - November 17th, 2021
- Gene editing: Great for medicine but ethical issues arise - November 17th, 2021
- Gene on, gene off: Chroma Medicine turns lights on with $125M to control gene expression with ex-Editas, Regeneron leaders - FierceBiotech - November 17th, 2021
- gene therapy | Description, Uses, Examples, & Safety ... - November 17th, 2021
- Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development - Yahoo Finance - November 17th, 2021
- CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes -... - November 17th, 2021
- 8 medical advances you may have missed during COVID-19 - AAMC - November 17th, 2021
- PNAS Papers on Woodrat Microbiome, Maternal Cannabis Use, Gene-Based Testing - GenomeWeb - November 17th, 2021